12:00 AM
 | 
Aug 14, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Thymitaq nolatrexed (AG337): Began Phase III testing

Zarix licensed Thymitaq from Agouron Pharmaceuticals Inc. (La Jolla, Calif.), a subsidiary of Pfizer Inc. (PFE, New York, N.Y.), which had ceased Phase...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >